MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints

Definium Therapeutics, Inc.

MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.
Phase 2b study in 198 adults with moderate-to-severe GAD met primary and key secondary endpoints; dose-response demonstrated.
MM120 was well-tolerated; adverse events mild-to-moderate, transient, consistent with LSD effects.
FDA granted Breakthrough Therapy Designation for MM120 in GAD; Phase 3 trials (Voyage, Panorama, Emerge) enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.